scholarly journals The Future of Insulin Pump Therapy in India and Developing Countries Resale and Recycle – A New Vision

2019 ◽  
Vol 4 (3) ◽  
Keyword(s):  
Developing Countries ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Insulin Pumps ◽  
Pump Therapy ◽  
Diabetes Technology ◽  
New Vision ◽  
The Many ◽  
Financial Recovery

Diabetes tsunami has hit India in a very devastating way in last decade. There is no doubt that CSII with Insulin pump Therapy has proved superior to MDI (multiple Dose Injection) therapy in Type1DM as well as Type2DM patients. Economics has been a very important issue while advocating the Pump to either patients, type 1 or type 2 Diabetes Mellitus patients. Out of 9 (Nine) patients using Insulin Pumps in our centre GANDHI CLINIC, PUNE, INDIA there are 5 Type 2 patients and 4 Type 1DM patients. Two Pumps are deposited at my Clinic due to the sad demise of the Type2DM patients. The relatives of these patients do wish to sell these pumps with some depreciation price i.e. at lower price than the new one. One patient (type2DM) has stopped using the Insulin pump due to the adverse advice from another healthcare provider who also wants to sell the pump at some discounted price. As per my survey in the Metro city of Pune (INDIA) approximately 700 insulin pumps are sold, out of these at least 5-7% of total pumps are not being used anymore. The unused pumps are at least 50 in number. Therefore revenue in terms of PUMPS in one region of INDIA is about 70000 US Dollars. Total number of pumps used in INDIA is 70000-72000 pumps approx. The total unused pumps by the patients could be about 3000 to 5000 pumps in total and thereby the revenue loss in this resource constrained country could be in millions of Dollars. This scenario is probably the same scene in many developing countries wherein the healthcare budgets are limited. In INDIA, Insulin Pump Therapy is not yet covered by Insurance policy of the patients. Since the pumps are usually purchased thru pocket expenses or with Loan or selling some assets like land or Gold, the relatives of the patients are not wrong in expecting some financial recovery after losing the most important thing i.e. the PERSON or even if patient does not want to continue the use of pump due to any reason. We do see refurbished cars sold and there are eligible and deserving candidates available who cannot purchase a new model of the Car. I am sure INDIA is an important market of Diabetes Technology related Products like Insulin Pump, similar to the many developing countries. This article is aimed at KOLs in Dialectology and Economists in the world for a basic policy change in favour of the patient care.

Retrospective Analysis and Patient Satisfaction Assessment of Insulin Pump Therapy in Patients with Type 2 Diabetes

2011 ◽  
Vol 104 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Chad K. Gentry ◽  
L. Brian Cross ◽  
Benjamin N. Gross ◽  
M. Shawn McFarland ◽  
William H. Bestermann
Keyword(s):  
Type 2 Diabetes ◽  
Patient Satisfaction ◽  
Retrospective Analysis ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Pump Therapy

scholarly journals CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e045650
Author(s):  
Sidse Kjærhus Nørgaard ◽  
Elisabeth Reinhardt Mathiesen ◽  
Kirsten Nørgaard ◽  
Tine Dalsgaard Clausen ◽  
Peter Damm ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Pump ◽  
Controlled Trial ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Acting Insulin ◽  
Pregnancy And Lactation ◽  
Randomised Controlled

IntroductionFaster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and lactation and on fetal growth and infant health.Methods and analysisAn open-label randomised controlled trial of pregnant women with type 1 or type 2 diabetes including women on multiple daily injection (MDI) therapy or insulin pump therapy. During a 2-year inclusion period, approximately 220 women will be randomised 1:1 to Fiasp or NovoRapid in early pregnancy and followed until 3 months after delivery. At 9, 21 and 33 gestational weeks and during planned induction of labour or caesarean section, women are offered blinded continuous glucose monitoring (CGM) for 7 days. Randomisation will stratify for type of diabetes and insulin treatment modality (MDI or insulin pump therapy, respectively). Health status of the infants will be followed until 3 months of age. The primary outcome is birth weight SD score adjusted for gestational age and gender. Secondary outcomes include maternal glycaemic control including glycated haemoglobin, preprandial and postprandial self-monitored plasma glucose levels, episodes of mild and severe hypoglycaemia, maternal gestational weight gain and weight retention, CGM time spent in, above and below target ranges as well as pregnancy outcomes including pre-eclampsia, preterm delivery, perinatal mortality and neonatal morbidity. Data analysis will be performed according to the intention-to-treat principle.Ethics and disseminationThe trial has been approved by the Regional Ethics Committee (H-19029966) on 7 August 2019. Results will be sought disseminated in peer-reviewed journals and at scientific meetings.Trial registration numberNCT03770767

scholarly journals The use of ultra-short acting insulin preparations for insulin pumps

2012 ◽  
Vol 58 (3) ◽  
pp. 46-50
Author(s):  
E A Andrianova
Keyword(s):  
Diabetes Mellitus ◽  
Children And Adolescents ◽  
Insulin Pump ◽  
Age Groups ◽  
Insulin Pump Therapy ◽  
Insulin Pumps ◽  
Pump Therapy ◽  
Short Acting ◽  
Acting Insulin ◽  
Short Acting Insulin

The data on the efficacy of using ultra-short acting insulin preparations in insulin pumps for children and adolescents presenting with diabetes mellitus. Insulin pump therapy in the patients of these age groups is finding an increasingly wider application as being more convenient for the users and leading to the improvement of glycemic control. One of the main advantages of modern insulin pump therapy is the possibility to maximally imitate the physiological profile of insulin secretion. The flexibility of both basal and bolus dosing regimens of insulin administration can be further increased by using ultra-short acting insulin preparations in insulin pumps. The choice of any of the three currently available analogs of ultra-short acting insulin guarantees their identical efficacy and safety in the children and adolescents with type 1 diabetes mellitus. They can be recommended as insulins of choice for the use in pump therapy

Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients

2005 ◽  
Vol 22 (8) ◽  
pp. 1037-1046 ◽  
Author(s):  
J. Wainstein ◽  
M. Metzger ◽  
M. Boaz ◽  
O. Minuchin ◽  
Y. Cohen ◽  
...  
Keyword(s):  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Pump Therapy ◽  
Multiple Daily Injections ◽  
Type 2 Diabetic

scholarly journals The role of insulin pump therapy for type 2 diabetes mellitus

2016 ◽  
Vol 33 (1) ◽  
pp. e2822 ◽  
Author(s):  
Zohar Landau ◽  
Itamar Raz ◽  
Julio Wainstein ◽  
Yosefa Bar-Dayan ◽  
Avivit Cahn
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Pump Therapy
Sign in / Sign up

Export Citation Format

Share Document